DrugDashboards

Carboplatin

Carboplatin · CARBOPLATIN 10 mg/mL · Injection, Solution · Intravenous · Hospira, Inc.

NDC 61703-0339-56 · 1 VIAL, MULTI-DOSE in 1 CARTON / 60 mL in 1 VIAL, MULTI-DOSE · ANDA · View full market →

The short version

9 companies supply this market — a reasonable cushion if one runs into trouble. It is in shortage right now — FDA lists the reason as “other”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$3.15per billing unit (50 MG)HCPCS J9045 · Jul 1, 2026
  • Part D plans paid (avg)$1.01per dosage unitgross, before rebates — matched by drug name · 2024
  • List price (WAC, as filed)$177.39per packagePfizer Inc. · Jul 1, 2026

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$59.13
Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 50 MG
$3.153
HCPCS J9045 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$424,032
9,662 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $53.36 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA076517
TE code
AP
Approval date
Oct 14, 2004
Patents / exclusivity
None on file

Shortage history

  • In shortage now — Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)Apr 28, 2023
    Other
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)Apr 28, 2023
    Other
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)Apr 28, 2023
    Other
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)Apr 28, 2023
    Other
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)Apr 28, 2023
    Delay in shipping of the drug
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)Apr 28, 2023
    Other
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)Apr 28, 2023
    Other
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)Apr 28, 2023
    Discontinuation of the manufacture of the drug
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)Apr 28, 2023
    Demand increase for the drug
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)Apr 28, 2023
    Other
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)Apr 28, 2023
    Other
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • Planned discontinuation — Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)Apr 28, 2023
  • In shortage now — Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)Apr 28, 2023
    Demand increase for the drug
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)Apr 28, 2023
    Demand increase for the drug
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)Apr 28, 2023
    Demand increase for the drug
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)Apr 28, 2023
    Other
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)Apr 28, 2023
    Discontinuation of the manufacture of the drug
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)Apr 28, 2023
    Discontinuation of the manufacture of the drug
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)Apr 28, 2023
    Other
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)Apr 28, 2023
    Other
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months

Recalls (this NDC)

  • Class I · CompletedNov 8, 2012
    Hospira Inc. — Crystallization: Product is being recalled due to visible particulates identified during a retain sample inspection. Findings have identified the particles as Carboplatin crystals.
  • Class I · CompletedNov 8, 2012
    Hospira Inc. — Crystallization: Product is being recalled due to visible particulates identified during a retain sample inspection. Findings have identified the particles as Carboplatin crystals.
  • Class III · TerminatedJul 2, 2012
    Hospira Inc. — Failed PH specification: The lots of Carboplatin Injection were manufactured from Carboplatin API lots which trended out of specification low pH.
  • Class II · TerminatedJun 27, 2012
    Hospira Inc. — The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are beig recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.

Manufacturers of Carboplatin (Injection, Solution)

LabelerStrengthFirst seenLast seen
BPI Labs LLCCARBOPLATIN 10 mg/mLJul 15, 2026Sep 3, 2026
Gland Pharma LimitedCARBOPLATIN 10 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.CARBOPLATIN 10 mg/mLJul 15, 2026Sep 3, 2026
Teva Parenteral Medicines, Inc.CARBOPLATIN 10 mg/mLJul 15, 2026Sep 3, 2026
Apotex Corp.CARBOPLATIN 10 mg/mLJul 15, 2026Sep 2, 2026
Eugia US LLCCARBOPLATIN 150 mg/15mLJul 15, 2026Sep 2, 2026
Eugia US LLCCARBOPLATIN 50 mg/5mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCCARBOPLATIN 10 mg/mLJul 15, 2026Sep 2, 2026
Natco Pharma USA LLCCARBOPLATIN 450 mg/45mLAug 5, 2026Sep 2, 2026
Natco Pharma USA LLCCARBOPLATIN 150 mg/15mLAug 5, 2026Sep 2, 2026
Natco Pharma USA LLCCARBOPLATIN 50 mg/5mLAug 5, 2026Sep 2, 2026
Natco Pharma USA LLCCARBOPLATIN 600 mg/60mLAug 5, 2026Sep 2, 2026
Teyro Labs Private LimitedCARBOPLATIN 150 mg/15mLJul 15, 2026Sep 2, 2026
Teyro Labs Private LimitedCARBOPLATIN 600 mg/60mLJul 15, 2026Sep 2, 2026
Teyro Labs Private LimitedCARBOPLATIN 50 mg/5mLJul 15, 2026Sep 2, 2026
Teyro Labs Private LimitedCARBOPLATIN 450 mg/45mLJul 15, 2026Sep 2, 2026
Eugia US LLCCARBOPLATIN 600 mg/60mLJul 15, 2026Aug 31, 2026
Eugia US LLCCARBOPLATIN 450 mg/45mLJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Carboplatin — NDC 61703-0339-56," retrieved September 3, 2026, https://drugdashboards.com/drug/61703033956.

Free to cite with attribution — see how the data is put together.